Dr. Wayne Gulliver
A Dermatologist experienced as a clinician, educator, administrator, clinical and basic science researcher. Has been in clinical practice for almost thirty years and has supervised over 250 clinical trials covering many aspects of dermatology with the focus in genetics, psoriasis, wound care, virology and hidradenitis suppurativa. He has more than 100 published papers authored or co-authored, as well as over 200 abstracts authored or co-authored.
Professor and Chair of the Discipline of Medicine, Memorial University of Newfoundland (2009-2011), as well as Head of Dermatology, Faculty of Medicine, Memorial University of Newfoundland (1989-2021). Adjunct Professor, Henan University of Traditional Chinese Medicine, and Zhengzhou University, Henan, PR China. Chair & Medical Director of NewLab Clinical Research Inc. (1996-2009), Chief Scientific Officer, NewLab Life Sciences (2009-2011). Former President of Matrixx Cosmetic Laser Clinic, Vice-President of Focus Continuing Education Inc., Vice-President of the Canadian Dermatology Association (1996-1997) and Chair of the organizing committee for the CDA meeting (1996-1997), St. John’s, Newfoundland. Former Chief, Division of Dermatology, Eastern Health, St. John’s, Newfoundland (1996-2008). Co-founder of Newfound Genomics (a Newfoundland & Labrador based genomics company). Former member of the Governing Council of the National Research Council (2003-2006); CEO of Advanced Immuni T Inc. (Canada) and Advanced Immuni T Inc. (USA) (2003-2005).
Member of the Editorial Board for the Journal of Cutaneous Medicine and Surgery and Medical Editor The Chronicle of Skin & Allergy. Reviewer for Clinical and Experimental Dermatology, the BMJ (British Journal of Dermatology UK) and British Journal of Dermatology. Previous member of the College of Reviewers for the Canada Research Chairs Program (2007-2010), Chair, Newfoundland and Labrador Association of Technology Industries (NATI) (2008/09), Chair and Board Member, Newfoundland and Labrador Science Centre.
Saturday APR 9, 2022
Be Informed about Recent Psoriasis Treatment Advances
- Analyze the bimekizumab clinical trial program, focusing on the efficacy and safety of bimekizumab in patients with moderate-to-severe psoriasis.
- Share first-hand experience with bimekizumab from Canadian trialists.
- Explore perspectives on the future landscape of psoriasis management in Canada.